Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts
Executive Summary
Melinta describes difficulties launching its new antibiotics at BIO CEO & Investor Conference; companies and other stakeholders urge Congress to enact package of incentives to reinvigorate antibiotic pipeline.
You may also be interested in...
Stock Watch: Pharma Castoffs Sink Without A Trace … Eventually
When a small biotech company acquires a failed drug from big pharma and plans to repeat the clinical studies expecting a positive result, is that not a definition of insanity?
Nabriva Faces Skepticism After Years Of Preparing For Novel Antibiotic Xenleta's Launch
Lefamulin was approved in the US to treat community-acquired bacterial pneumonia, providing a needed IV and oral drug initially in the hospital setting, but new antibiotics have been a tough sell.
Finance Watch: Alphamab's $100m Series A Continues Theme Of Big Investments In China Biopharma
The Suzhou-based drug developer brings in new cash as US venture deals take a holiday. Also, France's Genfit may go public in the US, Taiwan Liposome launches its IPO, and Bioblast's strategic review ends in a reverse merger.